Surface Pharmaceuticals, Inc. Announces $20 Million Series A ...
PR Newswire (press release)-3 hours ago
The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or
No comments:
Post a Comment